By: Jamie Herndon

At a moment when American medicine is reassessing long-standing orthodoxies around mental health, addiction, and consciousness itself, a striking new experiment is unfolding quietly on Long Island. According to an extensive report on Monday by The New York Post, patients at a newly launched Northwell Health research facility are being invited to do something that would have been unthinkable in mainstream medicine just a decade ago: consume full doses of psychedelic drugs, cannabis, and alcohol in environments deliberately designed to resemble living rooms, sports bars, and lounges, all under the watchful eye of physicians and psychologists.

This is not recreational indulgence masquerading as therapy, Northwell officials insist, but an ambitious attempt to understand how psychoactive substances behave when taken in realistic, everyday settings rather than sterile laboratory rooms. The research, spearheaded by the Feinstein Family human neuropsychopharmacology lab in Manhasset and expanded at the Center for Psychedelics Research and Treatment at Zucker Hillside Hospital, represents one of the boldest efforts yet to bridge the gap between controlled clinical science and lived human experience.

As The New York Post reported, the program is led by Dr. Nehal Vadhan, a veteran researcher who makes no effort to downplay the intensity of what participants experience. “We’re studying full doses that produce anywhere from a four- to a six-hour trip,” Vadhan explained, describing trials involving psilocybin, the psychoactive compound found in so-called magic mushrooms. In other studies, subjects ingest MDMA or cannabis in quantities far larger than those typically used in conventional research settings.

The emphasis, Vadhan told The New York Post, is on realism. Rather than asking subjects to take a puff of marijuana or a microdose of a psychedelic compound and then lie motionless under fluorescent lights, Northwell’s approach asks them to consume these substances all at once, as people commonly do outside the lab. “With cannabis, we’re asking them to consume it all at once, rather than puff on it throughout the day,” he said. “So they’re getting a massive hit of it right up front. We can really obtain very robust effects.”

The spaces where these experiments take place are as unconventional as the substances themselves. According to the information provided in The New York Post report, Northwell has constructed rooms that feel more like upscale apartments or trendy lounges than hospital wards. One room is bathed in blue-toned lighting, tailored for participants undergoing psychedelic sessions. Another glows green for cannabis studies. Plush seating, soothing classical music, curated visual displays, and even virtual-reality headsets offering calming landscapes are all part of the experience.

Elsewhere in the facility, researchers have built what amounts to a fully functioning bar. There are stools, dimmable lights, sports programming on high-definition televisions, and even pub signage donated by a local watering hole. Through a discreet one-way window, clinicians can slide beers, wine, or cocktails to participants while monitoring their behavior from behind glass, much like observers in a police interrogation room.

The goal, Vadhan emphasized to The New York Post, is not indulgence for its own sake. Patients, many of whom are already receiving psychiatric care within the Northwell system, are continuously evaluated. They answer questions, report on their mood states, and perform cognitive tasks designed to test memory, judgment, and impulse control. Sessions typically occur four days a week, with breaks in between to allow participants to recover and reflect.

The range of conditions under investigation underscores how far psychedelic research has come since the era when such substances were dismissed as fringe or dangerous. One ongoing study examines whether a full dose of psilocybin can alleviate social anxiety disorder, a condition that often proves resistant to traditional therapies. Another explores whether MDMA can safely address the so-called “negative symptoms” of schizophrenia, such as emotional withdrawal and lack of motivation—symptoms that are notoriously difficult to treat.

Clinical ketamine research is also being prepared, further broadening the center’s scope. Each project is carefully monitored, and while the environment may feel relaxed, the science is exacting. Therapists sit with participants during sessions, offering what Vadhan described to The New York Post as “guidance.” Their role is not to eliminate discomfort entirely, but to help subjects navigate challenging emotional terrain.

“The goal is not to make it completely comfortable the whole time,” Vadhan said. “Without some discomfort, there’s probably not much ability to change. You have to confront certain things that comprise your disorder.”

This philosophy marks a departure from earlier psychiatric models that sought to suppress symptoms at all costs. Instead, Northwell’s researchers appear to be betting that controlled exposure to altered states—when paired with professional support—can unlock insights and emotional breakthroughs unavailable through conventional medication alone.

Concerns about safety inevitably loom over such an enterprise, but Vadhan downplayed the risks in his comments to The New York Post. Extreme reactions, he said, are rare. Participants might become drowsy, euphoric, or verbally disinhibited. “Very rarely do we see any kind of aggression, any kind of anger,” he noted.

The facility’s alcohol studies, which involve consumption levels equivalent to three to five drinks per session, are similarly structured to reflect real-world behavior. Researchers are particularly interested in cravings and decision-making. After drinking, participants might be asked to recall number sequences, perform arithmetic, or choose between different options presented on a screen. These exercises help scientists understand how alcohol impairs cognition and judgment in everyday contexts.

Adjacent to the bar sits one of the program’s most striking features: a high-tech driving simulator. According to the information contained in The New York Post report, the simulator allows researchers to examine how intoxication affects driving behaviors such as braking, acceleration, and reaction time in scenarios like congested traffic or construction zones. While some participants may be experienced drinkers or cannabis users who believe they can “compensate,” the simulator offers objective data on whether that confidence is justified.

Crucially, no one is allowed to drive to or from these sessions. Transportation is arranged to ensure that even mildly impaired participants pose no risk to themselves or others once they leave the facility. “So even if they’re feeling a little bit buzzed when they leave here,” Vadhan explained to The New York Post, “there’s no danger.”

Northwell’s program arrives amid a broader reevaluation of drug policy and psychiatric treatment across the United States. As traditional antidepressants and antipsychotics show limited effectiveness for many patients, interest in psychedelics has surged among researchers and investors alike. Still, the sight of a hospital-sanctioned bar and rooms designed for people to get high would have been scandalous not long ago.

Critics may argue that such environments blur ethical lines or risk normalizing substance use. Supporters counter that ignoring how people actually consume drugs has hampered research for decades. By studying substances in settings that mirror real life, Northwell hopes to generate findings that translate more directly into clinical practice.

For now, the work remains tightly controlled, its ambitions carefully framed as scientific inquiry rather than cultural rebellion. Yet as The New York Post’s report makes clear, the symbolism is powerful. In place of stark white walls and whispered instructions, patients find couches, music, snacks, and sports highlights—a setting that acknowledges pleasure and vulnerability alongside pathology.

Whether Northwell’s experiment will reshape psychiatric care or provoke backlash remains to be seen. What is certain is that it represents a striking moment in modern medicine, one in which the boundaries between treatment, experience, and environment are being deliberately redrawn. As Vadhan and his colleagues continue their work, the results may help determine whether altered states of consciousness—once relegated to counterculture—can claim a legitimate, carefully regulated place in the future of mental health care.

As The New York Post reported, this is not simply about getting high under medical supervision. It is about confronting long-standing assumptions, testing uncomfortable hypotheses, and exploring whether healing sometimes requires stepping beyond the confines of conventional sobriety.